Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
2.

Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.

von Hardenberg J, Hartmann S, Nitschke K, Worst TS, Ting S, Reis H, Nuhn P, Weis CA, Erben P.

Clin Genitourin Cancer. 2019 Apr;17(2):145-153.e5. doi: 10.1016/j.clgc.2018.12.007. Epub 2018 Dec 21.

PMID:
30709785
3.

Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.

Nitschke K, Erben P, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Wahby S, Nuhn P, Boutros M, Michel MS, von Hardenberg J, Worst TS.

World J Urol. 2019 Jan 30. doi: 10.1007/s00345-019-02651-8. [Epub ahead of print]

PMID:
30701334
4.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
5.

Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.

von Hardenberg J, Worst TS, Westhoff N, Erben P, Fuxius S, Müller M, Bolenz C, Weiss C, Heinrich E.

Oncol Res Treat. 2018;41(10):627-633. doi: 10.1159/000490618. Epub 2018 Sep 10.

PMID:
30286478
6.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

7.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
8.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

9.

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 May 25;9(40):25935-25945. doi: 10.18632/oncotarget.25407. eCollection 2018 May 25.

10.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
11.

Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients.

John A, Baumgart A, Worst T, Heinzelbecker J.

Urol Int. 2018;100(3):279-287. doi: 10.1159/000486343. Epub 2018 Mar 7.

PMID:
29514158
12.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

13.

Letter to the Editor-Elbow Grease and OxiClean™ for Cleaning Fentanyl- and Acetylfentanyl-contaminated Surfaces.

Froelich NM, Sprague JE, Worst TJ.

J Forensic Sci. 2018 Jan;63(1):336-338. doi: 10.1111/1556-4029.13675. No abstract available.

PMID:
29314013
14.

Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane.

Menck K, Sönmezer C, Worst TS, Schulz M, Dihazi GH, Streit F, Erdmann G, Kling S, Boutros M, Binder C, Gross JC.

J Extracell Vesicles. 2017 Sep 26;6(1):1378056. doi: 10.1080/20013078.2017.1378056. eCollection 2017.

15.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
16.

Impact of Altered WNT2B Expression on Bladder Wall Fibroblasts: Implications for Apoptosis Regulation in the Stroma of the Lower Urinary Tract.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Kriegmair MC, Erben P, Pfalzgraf D.

Urol Int. 2017;99(4):476-483. doi: 10.1159/000481440. Epub 2017 Oct 31.

PMID:
29131138
17.

The EEF1A2 gene expression as risk predictor in localized prostate cancer.

Worst TS, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Steidler A, von Hardenberg J, Michel MS, Erben P.

BMC Urol. 2017 Sep 18;17(1):86. doi: 10.1186/s12894-017-0278-3.

18.

Tumor-derived exosomes modulate PD-L1 expression in monocytes.

Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M.

Sci Immunol. 2017 Jul 28;2(13). pii: eaah5509. doi: 10.1126/sciimmunol.aah5509.

PMID:
28754746
19.

Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.

von Hardenberg J, Schwartz M, Werner T, Fuxius S, Strauss A, Worst TS, Nuhn P, Bolenz C, Heinrich E.

Urol Int. 2017;99(4):414-421. doi: 10.1159/000477943. Epub 2017 Jul 13. Review.

PMID:
28700990
20.

Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Weis CA, Kriegmair MC, Erben P, Pfalzgraf D.

World J Urol. 2017 Nov;35(11):1701-1711. doi: 10.1007/s00345-017-2060-2. Epub 2017 Jun 20.

PMID:
28634911
21.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

22.

Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.

Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, Bugert P, Michel MS, Boutros M.

Mol Cell Proteomics. 2017 Jun;16(6):998-1008. doi: 10.1074/mcp.M117.068577. Epub 2017 Apr 9.

23.

RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.

Worst TS, Meyer Y, Gottschalt M, Weis CA, von Hardenberg J, Frank C, Steidler A, Michel MS, Erben P.

Int J Oncol. 2017 Mar;50(3):920-932. doi: 10.3892/ijo.2017.3872. Epub 2017 Feb 10.

PMID:
28197629
24.

[Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics].

Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R.

Urologe A. 2017 Feb;56(2):202-207. doi: 10.1007/s00120-016-0217-z. Review. German.

PMID:
27604705
25.

Cisplatin-Based Chemotherapy for Testicular Germ Cell Tumors: Complication Rates of Peripheral versus Central Venous Administration.

Worst T, Sautter L, John A, Weiss C, Häcker A, Heinzelbecker J.

Urol Int. 2016;96(2):177-82. doi: 10.1159/000442003. Epub 2015 Dec 18.

PMID:
26681435
26.

The α- and β-Adrenergic Antagonist Controversy with Sympathomimetic Agents.

Banks ML, Worst TJ, Rusyniak DE, Sprague JE.

J Emerg Med. 2015 Dec;49(6):e209-10. doi: 10.1016/j.jemermed.2015.06.004. Epub 2015 Aug 12. No abstract available.

27.

IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.

Worst TS, Reiner V, Gabriel U, Weiß C, Erben P, Martini T, Bolenz C.

Adv Urol. 2014;2014:184602. doi: 10.1155/2014/184602. Epub 2014 Jul 8.

28.

Synthetic cathinones ("bath salts").

Banks ML, Worst TJ, Rusyniak DE, Sprague JE.

J Emerg Med. 2014 May;46(5):632-42. doi: 10.1016/j.jemermed.2013.11.104. Epub 2014 Feb 22. Review.

29.

[Abstracts at congresses of the German Society of Urology. Trends and quality].

von Hardenberg J, Worst T, Weiß C, Michel MS.

Urologe A. 2013 Sep;52(9):1296-301. doi: 10.1007/s00120-013-3304-4. German.

PMID:
23942740
30.

Factors influencing local tumor control in patients with neoplastic pulmonary nodules treated with microwave ablation: a risk-factor analysis.

Vogl TJ, Worst TS, Naguib NN, Ackermann H, Gruber-Rouh T, Nour-Eldin NE.

AJR Am J Roentgenol. 2013 Mar;200(3):665-72. doi: 10.2214/AJR.12.8721.

PMID:
23436860
31.

Apo-AII is an elevated biomarker of chronic non-human primate ethanol self-administration.

Freeman WM, Gooch RS, Lull ME, Worst TJ, Walker SJ, Xu AS, Green H, Pierre PJ, Grant KA, Vrana KE.

Alcohol Alcohol. 2006 May-Jun;41(3):300-5. Epub 2006 Mar 31.

PMID:
16581821
32.

Transcriptome analysis of frontal cortex in alcohol-preferring and nonpreferring rats.

Worst TJ, Tan JC, Robertson DJ, Freeman WM, Hyytia P, Kiianmaa K, Vrana KE.

J Neurosci Res. 2005 May 15;80(4):529-38.

PMID:
15846778
33.

Alcohol and gene expression in the central nervous system.

Worst TJ, Vrana KE.

Alcohol Alcohol. 2005 Jan-Feb;40(1):63-75. Epub 2004 Nov 29. Review.

PMID:
15569717
34.

Manganese-induced cytotoxicity in dopamine-producing cells.

Stredrick DL, Stokes AH, Worst TJ, Freeman WM, Johnson EA, Lash LH, Aschner M, Vrana KE.

Neurotoxicology. 2004 Jun;25(4):543-53.

PMID:
15183009
35.

Functional genomic analysis in pain research using hybridization arrays.

Walker SJ, Worst TJ, Freeman WM, Vrana KE.

Methods Mol Med. 2004;99:239-53.

PMID:
15131342
36.

The future of proteomics in the study of alcoholism.

Kasinathan C, Vrana K, Beretta L, Thomas P, Gooch R, Worst T, Walker S, Xu A, Pierre P, Green H, Grant K, Manowitz P.

Alcohol Clin Exp Res. 2004 Feb;28(2):228-32.

37.

Systematic screening of gene expression using a cDNA macroarray.

Worst TJ, Freeman WM, Walker SJ, Vrana KE.

Methods Mol Med. 2003;79:243-59. No abstract available.

PMID:
12506701
38.

Semiquantitative real-time PCR for analysis of mRNA levels.

Walker SJ, Worst TJ, Vrana KE.

Methods Mol Med. 2003;79:211-27. No abstract available.

PMID:
12506699
39.

Parthenogenetic stem cells in nonhuman primates.

Cibelli JB, Grant KA, Chapman KB, Cunniff K, Worst T, Green HL, Walker SJ, Gutin PH, Vilner L, Tabar V, Dominko T, Kane J, Wettstein PJ, Lanza RP, Studer L, Vrana KE, West MD.

Science. 2002 Feb 1;295(5556):819. No abstract available.

40.

The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.

Sprague JE, Worst TJ, Haynes K, Mosler CR, Nichols DE, Kane MD.

Cell Mol Neurobiol. 2001 Feb;21(1):53-64.

PMID:
11440198

Supplemental Content

Support Center